|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NeuroSearch A/S, Ballerup, Denmark (D.S., C.H., T.H.J., U.S.S., E.Ø.N., K.S.N., P.C.); and Department of Physiology, University College London, London, United Kingdom (R.D.T., P.P.)
SK channels are small conductance Ca2+-activated K+ channels important for the control of neuronal excitability, the fine tuning of firing patterns, and the regulation of synaptic mechanisms. The classic SK channel pharmacology has largely focused on the peptide apamin, which acts extracellularly by a pore-blocking mechanism. 1-Ethyl-2-benzimidazolinone (1-EBIO) and 6,7-dichloro-1H-indole-2,3-dione 3-oxime (NS309) have been identified as positive gating modulators that increase the apparent Ca2+ sensitivity of SK channels. In the present study, we describe inhibitory gating modulation as a novel principle for selective inhibition of SK channels. In wholecell patch-clamp experiments, the compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reversibly inhibited recombinant SK3-mediated currents (human SK3 and rat SK3) with potencies around 100 nM. However, in contrast to known pore blockers, NS8593 did not inhibit 125I-apamin binding. Using excised patches, it was demonstrated that NS8593 decreased the Ca2+ sensitivity by shifting the activation curve for Ca2+ to the right, only slightly affecting the maximal Ca2+-activated SK current. NS8593 inhibited all the SK1-3 subtypes Ca2+-dependently (Kd = 0.42, 0.60, and 0.73 µM, respectively, at 0.5 µM Ca2+), whereas the compound did not affect the Ca2+-activated K+ channels of intermediate and large conductance (hIK and hBK channels, respectively). The site of action was accessible from both sides of the membrane, and the NS8593-mediated inhibition was prevented in the presence of a high concentration of the positive modulator NS309. NS8593 was further tested on mouse CA1 neurons in hippocampal slices and shown to inhibit the apaminand tubocurarine-sensitive SK-mediated afterhyperpolarizing current, at a concentration of 3 µM.
Received for publication May 24, 2006.
Accepted for publication August 22, 2006.
Address correspondence to: Dr. Palle Christophersen, NeuroSearch A/S, Pederstrupvej 93, DK 2750 Ballerup, Denmark. E-mail: pc{at}neurosearch.dk
This article has been cited by other articles:
![]() |
C. Hougaard, M. L. Jensen, T. J. Dale, D. D. Miller, D. J. Davies, B. L. Eriksen, D. Strobaek, D. J. Trezise, and P. Christophersen Selective Activation of the SK1 Subtype of Human Small-Conductance Ca2+-Activated K+ Channels by 4-(2-Methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic Acid tert-Butyl Ester (GW542573X) Is Dependent on Serine 293 in the S5 Segment Mol. Pharmacol., September 1, 2009; 76(3): 569 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sankaranarayanan, G. Raman, C. Busch, T. Schultz, P. I. Zimin, J. Hoyer, R. Kohler, and H. Wulff Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure Mol. Pharmacol., February 1, 2009; 75(2): 281 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Canavier, S. A. Oprisan, J. C. Callaway, H. Ji, and P. D. Shepard Computational Model Predicts a Role for ERG Current in Repolarizing Plateau Potentials in Dopamine Neurons: Implications for Modulation of Neuronal Activity J Neurophysiol, November 1, 2007; 98(5): 3006 - 3022. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Shepard, C. C. Canavier, and E. S. Levitan Ether-a-go-go Related Gene Potassium Channels: What's All the Buzz About? Schizophr Bull, November 1, 2007; 33(6): 1263 - 1269. [Abstract] [Full Text] [PDF] |
||||